Loading...

Brilliant Violet 421™ anti-mouse Ly-6G Antibody

Pricing & Availability
Clone
1A8 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus G
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1A8_BV421_032911
C57BL/6 mouse bone marrow cells were stained with Ly-6G (clone 1A8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.
  • 1A8_BV421_032911
    C57BL/6 mouse bone marrow cells were stained with Ly-6G (clone 1A8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.
  • 1A8_BV421_Ly-6G_Antibody2_IHC_122916
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS and 5% rat/mouse serum for one hour at room temperature. Then the section was stained with 2.5 µg/mL of Ly-6G (clone 1A8) Brilliant Violet 421™ (red), 5 µg/mL of CD3 Alexa Fluor® 647 (green), and 5 µg/mL of B220 Alexa Fluor® 488 (blue) overnight at 4°C. The image was captured by 10X objective.
Compare all formats See Brilliant Violet 421™ spectral data See high resolution IHC-F data...
Cat # Size Price Quantity Check Availability Save
127627 125 µL £117
Check Availability


Need larger quantities of this item?
Request Bulk Quote
127628 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Ly-6G transfected EL-4J cell line.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416.

Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
  2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
  3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
  4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
  5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
  6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
  7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
  8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
  9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
  10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
  11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
  12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
  13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
  14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
  15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
  17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
  19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
  20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  2. Fang C, et al. 2022. J Pathol. 256:310. PubMed
  3. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  4. Mirchandani AS, et al. 2022. Nat Immunol. 23:927. PubMed
  5. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  6. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  7. Glaubitz J, et al. 2023. Gut. :. PubMed
  8. Ren ZN, et al. 2022. Acta Pharmacol Sin. 43:1264. PubMed
  9. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
  10. Yang J, et al. 2022. Cancer Res. 82:4247. PubMed
  11. Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed
  12. Banka AL, et al. 2023. Nat Commun. 14:2462. PubMed
  13. Distel JS, et al. 2023. PLoS Pathog. 19:e1011173. PubMed
  14. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  15. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  16. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  17. Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed
  18. Han H, et al. 2021. Front Pharmacol. 12:726586. PubMed
  19. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  20. Mansouri N, et al. 2019. JCI Insight. 4:e128060. PubMed
  21. Wang L, et al. 2020. Cells. 0.458333333. PubMed
  22. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  23. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  24. Brandt S, et al. 2020. J Am Soc Nephrol. 31:2589. PubMed
  25. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  26. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  27. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  28. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  29. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
  30. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
  31. Angelidis I, et al. 2019. Nat Commun. 10:963. PubMed
  32. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  33. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  34. Green DP, et al. 2019. Neuron. 101:412. PubMed
  35. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  36. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  37. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  38. Barman PK, et al. 2019. J Immunol. 202:2720. PubMed
  39. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  40. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  41. Yu Y, et al. 2022. Nat Commun. 13:6857. PubMed
  42. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  43. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
  44. Baudoux T, et al. 2018. Sci Rep. 4.0375. PubMed
  45. Hassan AO, et al. 2021. Cell Reports. 36(4):109452. PubMed
  46. Vicencio JM, et al. 2022. Cell Death Dis. 13:274. PubMed
  47. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  48. Köhler D, et al. 2020. Nat Commun. 11:1315. PubMed
  49. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  50. Zeng Z, et al. 2022. Oncogene. :. PubMed
  51. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  52. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  53. Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed
  54. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  55. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  56. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  57. Ermert D, et al. 2016. PLoS Pathog. 11: 1005043. PubMed
  58. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  59. Pundir P, et al. 2020. Cell Host & Microbe. 26(1):114-122. PubMed
  60. Hasegawa T, et al. 2020. Sci Rep. 10:13480. PubMed
  61. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  62. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  63. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  64. Kullberg M, et al. 2015. Nanomedicine. 11: 1355-1363. PubMed
  65. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  66. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  67. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  68. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  69. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  70. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  71. Gardner P, et al. 2017. Sci Rep. 7:40830. PubMed
  72. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  73. Morein D, et al. 2021. Cells. 10: . PubMed
  74. La Salvia S, et al. 2020. Am J Physiol Renal Physiol. 319:F868. PubMed
  75. Bertuzzi M, et al. 2014. PLoS Pathog. 10:1004413. PubMed
  76. Harding CL, et al. 2020. Front Cell Infect Microbiol. 10:328. PubMed
  77. Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed
  78. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  79. Herbst S, et al. 2015. EMBO Mol Med. 30:240. PubMed
  80. Zheng C, et al. 2021. J Extracell Vesicles. 10:e12109. PubMed
  81. Li H, et al. 2021. J Clin Invest. 131:. PubMed
  82. Xiong S, et al. 2020. J Clin Invest. 130:3684. PubMed
  83. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
  84. Nepal S, et al. 2019. Proc Natl Acad Sci U S A. 116:16513. PubMed
  85. Kennedy J, et al. 2014. J Exp Med. 211:2519. PubMed
RRID
AB_10897944 (BioLegend Cat. No. 127627)
AB_10897944 (BioLegend Cat. No. 127628)

Antigen Details

Structure
A 21-35 kD GPI-anchorded membrane protein
Distribution

Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.

Cell Type
Granulocytes, Macrophages, Monocytes
Biology Area
Immunology, Innate Immunity
Antigen References

Fleming TJ, et al. 1993. J. Immunol. 151:2399.

Gene ID
546644 View all products for this Gene ID
UniProt
View information about Ly-6G on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

View All Ly-6G Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse Ly-6G 1A8 IHC-F,SB
Purified anti-mouse Ly-6G 1A8 FC,IHC-F,IHC-P,SB
Biotin anti-mouse Ly-6G 1A8 FC,IHC
FITC anti-mouse Ly-6G 1A8 FC
PE anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 647 anti-mouse Ly-6G 1A8 FC,IHC-F,SB
Pacific Blue™ anti-mouse Ly-6G 1A8 FC
APC anti-mouse Ly-6G 1A8 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G 1A8 FC
PE/Cyanine7 anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 700 anti-mouse Ly-6G 1A8 FC,IHC
APC/Cyanine7 anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 488 anti-mouse Ly-6G 1A8 FC,IHC-F,SB
Brilliant Violet 421™ anti-mouse Ly-6G 1A8 FC,IHC-F
Brilliant Violet 570™ anti-mouse Ly-6G 1A8 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G 1A8 FC,Depletion,IHC
Brilliant Violet 510™ anti-mouse Ly-6G 1A8 FC
Purified anti-mouse Ly-6G (Maxpar® Ready) 1A8 FC,CyTOF®,WB
Brilliant Violet 650™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 711™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 605™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 785™ anti-mouse Ly-6G 1A8 FC
PE/Dazzle™ 594 anti-mouse Ly-6G 1A8 FC
APC/Fire™ 750 anti-mouse Ly-6G 1A8 FC
PerCP anti-mouse Ly-6G 1A8 FC
TotalSeq™-A0015 anti-mouse Ly-6G 1A8 PG
TotalSeq™-C0015 anti-mouse Ly-6G 1A8 PG
TotalSeq™-B0015 anti-mouse Ly-6G 1A8 PG
Spark Blue™ 550 anti-mouse Ly-6G 1A8 FC
Spark NIR™ 685 anti-mouse Ly-6G 1A8 FC
Spark YG™ 593 anti-mouse Ly-6G 1A8 FC
APC/Fire™ 810 anti-mouse Ly-6G Antibody 1A8 FC
PE/Cyanine5 anti-mouse Ly-6G 1A8 FC
PE/Fire™ 810 anti-mouse Ly-6G Antibody 1A8 FC
Spark UV™ 387 anti-mouse Ly-6G 1A8 FC
PE/Fire™ 640 anti-mouse Ly-6G 1A8 FC
Spark YG™ 570 anti-mouse Ly-6G 1A8 IHC-F,FC
Spark Red™ 718 anti-mouse Ly-6G (Flexi-Fluor™) 1A8 FC
Spark Blue™ 574 anti-mouse Ly-6G (Flexi-Fluor™) 1A8 FC
Go To Top Version: 5    Revision Date: 01/06/2017

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account